CeriBell, Inc. (CBLL) on Monday, announced that the U.S. Food and Drug Administration has given Breakthrough Device Designation to a monitor for detecting Large Vessel Occlusion strokes, specifically designed for use in hospitals.
This new system is the first of its kind, utilizing Ceribell's existing EEG technology along with an AI-driven algorithm, which allows for quicker detection of LVO strokes in patients within the hospital.
This latest designation builds on recent FDA approvals for Ceribell's technologies aimed at detecting seizures and monitoring delirium.
Ceribell mentioned that this device could really help cut down the time it takes to identify strokes in hospitals because quicker detection can lead to much better outcomes for patients.
CBLL is currently trading at $21.97, up $0.67 or 3.12 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.